Trastuzumab (Herceptin®) was first approved by the U.S. Food and Drug Administration (FDA) in 1998 for the treatment of human epidermal growth factor receptor (HER2) positive breast cancer (1). The gene discussed is ERBB2; the disease is breast cancer.